Fenofibrate and Heart Failure Outcomes in Patients With Type 2 Diabetes: Analysis From ACCORD.
Joao Pedro FerreiraFrancisco Vasques-NóvoaDiana FerrãoFrancisca SaraivaInês Falcão-PiresJoão Sérgio NevesAbhinav SharmaPatrick RossignolFaiez ZannadAdelino Leite-MoreiraPublished in: Diabetes care (2022)
In patients with T2D treated with simvastatin, fenofibrate reduced the composite of HF hospitalizations or cardiovascular mortality, an effect that was seen predominantly in patients with standard background glucose-lowering therapy.